EC
TVTX icon

Elmind Capital’s Travere Therapeutics TVTX Stock Holding History

Elmind Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
292,600
+115,000
+65% +$5.1M 4.18% 10
2026
Q1 		$5.28M Buy
177,600
+67,600
+61% +$2.02M 1.5% 21
2025
Q4 		$4.2M Buy
+110,000
New +$3.58M 1.24% 21

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Elmind Capital's TVTX Position: Q2 2026 in Review

Elmind Capital increased its Travere Therapeutics (TVTX) stake by 65% in Q2 2026, buying an estimated $5.1M and bringing the position to 292,600 shares worth $16.6M. The position accounts for 4.18% of the portfolio, ranked #10.

Elmind Capital first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Elmind Capital held 292,600 shares of Travere Therapeutics worth $16.6M as of Q2 2026.
  • Elmind Capital bought 115,000 Travere Therapeutics shares in Q2 2026, an estimated $5.1M.
  • Travere Therapeutics made up 4.18% of Elmind Capital's portfolio in Q2 2026, its #10 holding.
  • Elmind Capital first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.